Sort
64,565 grants matching “drug discovery”
Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy
$687,030A Thomas Look · Dana-Farber Cancer Inst · P01 · FY2011 · CA
Conus Peptides and Their Receptor Targets
$687,001Baldomero M Olivera · University Of Utah · P01 · FY2009 · GM
Curaxin-137, A New Lead for Anti-Trypanosome Drug Discovery - Resubmission - 1
$686,979Kojo Mensa-Wilmot · University Of Georgia · R01 · FY2018 · AI
Proteomics-based Drug Discovery in Human Osteoblasts
$686,821Michael William Long · Velcura Therapeutics, Inc. · R44 · FY2006 · AG
Proteomics-based Drug Discovery in Human Osteoblasts
$686,821Velcura Therapeutics, Inc. · R44 · FY2005 · AG
A Scalable Neuron-Based High-Throughput Screening Platform for the Discovery of Compounds that Restore Protein Expression Caused by Genetic Haploinsufficiency
$686,767Gavin R Rumbaugh · Scripps Florida · R01 · FY2019 · MH
Preclinical validation of ABHD5 as a target for treatment of obesity.
$686,724James G Granneman · Wayne State University · R01 · FY2015 · DK
Natural Resistance to Mycobacterium Tuberculosis Infection
$686,622W. Henry Henry Boom · Case Western Reserve University · U01 · FY2016 · AI
Natural Resistance to Mycobacterium Tuberculosis Infection
$686,622W. Henry Henry Boom · Case Western Reserve University · U01 · FY2017 · AI
Investigating nanobodies to target multidrug resistant bacterial pathogens
$686,587Bryan William Davies · University Of Texas At Austin · R01 · FY2022 · AI
Investigating nanobodies to target multidrug resistant bacterial pathogens
$686,587Bryan William Davies · University Of Texas At Austin · R01 · FY2023 · AI
Investigating nanobodies to target multidrug resistant bacterial pathogens
$686,587Bryan William Davies · University Of Texas At Austin · R01 · FY2021 · AI
Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS
$686,517Christopher Chad Quarles · University Of Tx Md Anderson Can Ctr · R61 · FY2023 · NS
Rational optimization of combinatorial therapies for the treatment of rare cystic fibrosis variants
$686,508Jonathan Patrick Schlebach · Purdue University · R01 · FY2025 · HL
Clinical Core
$686,484Brian Wigdahl · Temple Univ Of The Commonwealth · P30 · FY2016 · MH
Discovery of functionally selective Alzheimer's disease therapeutics
$686,442Derek A Schreihofer · University Of North Texas Hlth Sci Ctr · R01 · FY2021 · AG
Relationships between APP and Mitochondria
$686,438Heather M. Wilkins · University Of Kansas Medical Center · R01 · FY2025 · AG
Contributions of aberrant synaptic protein monoaminylation to opiate use disorder
$686,377Ian S. Maze · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · DA
Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
$686,377Pearlie K Epling-Burnette · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2009 · CA
Genomic-wide Kinase Sequencing of Pediatric Brain Tumors
$686,328Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2007 · CA
Leadership, Planning, and Evaluation
$686,254Stanton L Gerson · Case Western Reserve University · P30 · FY2022 · CA
Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline
$686,250Philip Jon Rosenthal · University Of California, San Francisco · R01 · FY2024 · AI
Molecular pathways affected by drugs that disrupt Na+ and lipid homeostasis in malaria parasites
$686,225Akhil B Vaidya · Drexel University · R01 · FY2024 · AI
Novel Therapy to Inhibit IPMN Progression
$686,204Mokenge P. Malafa · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.
$686,190Rudolph Emile Tanzi · Massachusetts General Hospital · R01 · FY2019 · AG